1L CT (HR+HER2-): Active treatments
•
The combination of bevacizumab plus taxanes improves PFS and ORR, but not OS versus CT
alone and
should also be considered
a first-line CT option
[SEOM 2015]
•
Bevacizumab combined with a CT as 1st or 2nd line therapy for MBC provides only a
moderate benefit in PFS and no benefit in OS. The absence of known predictive factors for
bevacizumab efficacy renders recommendations on its use difficult. Bevacizumab can only
therefore be considered as an option in
selected cases
in these settings and is not
recommended after 1st/2nd line
[ESMO 2016]
Role of bevacizumab
Gavila et al CTO 2015; Cardoso et al Ann Oncol 2016;
